Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive high dose chemotherapy at the time of diagnosis, genetic testing is essential for identifying the oncogenic drivers. The identification of AML subtypes allows physicians to offer more targeted treatment options, which are particularly beneficial for those patients who experience relapse or refractory AML.